Physician profile
Sanjay V Shankar
NPI 1881893121
$11,897.53
in general payments reported to CMS, 2019-2025
39 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $1,376 · 2021: $1,566 · 2022: $2,377 · 2023: $2,028 · 2024: $2,030 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,658 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,657.68 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,472.89 | 2019-2025 | Gallant, Jot Dx, Aveir |
| Abiomed | $1,192.86 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $769.48 | 2019-2025 | Lifevest |
| Medtronic, INC. | $746.18 | 2021-2025 | Corevalve Evolut R, Micra, Azure Xt Dr Mri Surescan |
| Boston Scientific Corporation | $689.96 | 2019-2025 | Rotapro, Accolade Sr |
| Novartis Pharmaceuticals Corporation | $686.58 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $579.94 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.63 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $301.95 | 2019-2023 | Xarelto |
| Pfizer INC. | $247.60 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $238.60 | 2021-2023 | Uptravi, Opsumit |
| Amgen INC. | $234.14 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $213.36 | 2019-2025 | Farxiga, Wainua |
| Cleerly, INC. | $165.87 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Atricure, INC. | $154.27 | 2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $150.00 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $128.11 | 2024 | Venclose Maven Catheter |
| Esperion Therapeutics, INC. | $122.84 | 2020-2024 | Nexletol |
| Heartflow, INC. | $117.72 | 2023 | Ffrct |
| Edwards Lifesciences Corporation | $108.29 | 2020-2021 | |
| Biosense Webster, INC. | $102.42 | 2024 | Carto 3 |
| Bridgebio Pharma, INC. | $99.04 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $95.44 | 2020-2024 | |
| Daiichi Sankyo INC. | $80.47 | 2023 | Injectafer |
| Chiesi USA, INC. | $80.12 | 2020-2022 | |
| Shockwave Medical, INC | $77.85 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.23 | 2021-2025 | Camzyos, Eliquis |
| Inspire Medical Systems, INC. | $70.53 | 2023-2025 | Inspire |
| Medtronic Vascular, INC. | $67.02 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $58.59 | 2024-2025 | Amvuttra |
| Novo Nordisk INC | $47.58 | 2022-2023 | Ozempic |
| Zoll Respicardia, INC. | $46.49 | 2023-2024 | Remede System |
| Philips North America LLC | $45.14 | 2024 | (Bq9) Coronary Ivus, (Ck4) Mcot |
| Kiniksa Pharmaceuticals International, Plc | $33.20 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $29.87 | 2020-2021 | |
| Cook Medical LLC | $29.39 | 2021 | |
| Kestra Medical Technology Services, INC. | $23.30 | 2024 | Assure Wcd |
| Astellas Pharma US INC | $23.29 | 2020 | |
| Preventice Services, LLC | $14.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Shankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.